We are working to defeat cancer with data driven technology

Personalising cancer care with AI-powered prediction of treatment response

Latest Updates

  • FESTIVAL OF BIOLOGICS 2023!

    Thrilled to share that Curenetics was proudly present at the Festival of Biologics 2023, held from October 10th to 12th. We seized the opportunity to collaborate, learn, and contribute to shaping the future of biologics. Our team was truly inspired, enlightened, and captivated by the innovative discussions and experiences.

    Learn More

  • BioJapan2023 with London & Partners' Grow London Global Programme

    Curenetics was honoured to participate in BioJapan2023, Asia's Pharma Partnering Conference held in Yokohama on October 11th and 12th. As active members of the London & Partners’ Grow London Global Programme.

    Read Bio

  • AI-Enabled Oral Cancer assay - qMIDS

    Curenetics has joined forces with Queen Mary University London (QMUL) and Oracle Cancer Trust, supported by the South East Health Technologies Alliance (SEHTA) and funded by the NIHR (National Institute for Health and Care Research) to unveil the revolutionary AI-Enabled Oral Cancer assay - qMIDS.

    Read Press release

The Growing Challenge

Over 3 million patients are living with cancer in the UK alone, with 1,000 new diagnoses every day.

The UK cancer survival rate falls behind many other developed countries and outcomes for patients are extremely variable.

Just 20-30% of cancer patients respond well to the treatment they are offered, which can cost up to £90,000 per patient. In every 100 patients treated with immunotherapy, up to 55 will experience side effects which can be severe or even life-threatening. Toxicities attack the skin, colon, endocrine organs, liver, and lungs. Many more patients undergo immunotherapy treatment only to suffer from non-response or eventual relapse.

Current Prediction Methods

We have seen extraordinary advances in cancer treatment. However, methods used to predict the likelihood of success for individual patients are ineffective.

There are multiple factors involved in the varied responses to immunotherapy that patients experience. These can include gene variations, medical history, and physical makeup.

Yet the most common predictive methods for immunotherapy response currently are PD-L1 and CPS Score which use a single bio-marker to recommend a patient’s likelihood of success. This simplistic approach means that often patients do not respond as expected, resulting in life-affecting side effects, relapse, and too often, mortality.

Our Vision

Cancer is a devastating diagnosis for any individual so it is key to improving the outcomes for cancer patients.

The Curenetics AI-powered prediction tool enables patients and doctors to make well-informed decisions about the best route of cancer treatment.

Patients can enjoy a higher level of certainty that the precious energy, time, and resources spent on immunotherapy will have a positive impact on their lives. If treatment is likely to be ineffectual, a different course of action can be explored on an individual basis. 

Cancer is a devastating diagnosis. We hope to improve the journey by identifying the right course of treatment at the best time.

Click the link to learn how.